The quantification of drug risks in practice.
作者信息
Lee D, Bergman U
机构信息
Department of Clinical Pharmacology, Karolinska Institute, Huddinge University Hospital, Sweden.
出版信息
WHO Reg Publ Eur Ser. 1993;45:79-95.
PMID:8442852
Abstract
摘要
相似文献
1
The quantification of drug risks in practice.实践中药物风险的量化。
WHO Reg Publ Eur Ser. 1993;45:79-95.
2
Drug utilization studies within the VIDEOFAR project.视频远距离研究项目中的药物利用研究。
Ann Ist Super Sanita. 1991;27(2):201-6.
3
Postmarketing surveillance and other epidemiologic uses of drug prescription data in the United States.美国药品处方数据的上市后监测及其他流行病学用途。
Ann Ist Super Sanita. 1991;27(2):235-7.
4
Some thoughts on the reporting of adverse events in phase II cancer clinical trials.关于癌症II期临床试验中不良事件报告的一些思考。
J Clin Oncol. 2006 Aug 20;24(24):3821-2. doi: 10.1200/JCO.2006.06.9856.
5
[The need for 'postmarketing surveillance'].[上市后监测的必要性]
Ned Tijdschr Geneeskd. 1999 Apr 3;143(14):711-3.
6
Hepatitis B vaccination and multiple sclerosis: a data mining perspective.乙肝疫苗接种与多发性硬化症：数据挖掘视角
Pharmacoepidemiol Drug Saf. 2007 Aug;16(8):943-5. doi: 10.1002/pds.1420.
7
FDA attempting to overcome major roadblocks in monitoring drug safety.美国食品药品监督管理局正在试图克服药品安全监测中的重大障碍。
J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. doi: 10.1093/jnci/97.12.872.
8
Adverse drug reactions and reporting.药物不良反应与报告
Clin J Oncol Nurs. 2000 Jul-Aug;4(4):181, 184.
9
An overview of spontaneous reporting of adverse drug reactions (ARDs) in Zimbabwe.
Cent Afr J Med. 2000 Jan;46(1):23-4.
10
European commission consultation on pharmacovigilance.欧盟委员会关于药物警戒的咨询。
Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):108-9. doi: 10.1002/pds.1526.
Zotero 插件